FibroVera AHS
On sale on the US market (according to the DSLD)
Arthur Andrew Medical, food supplement from the US market
FibroVera AHS (Arthur Andrew Medical), a food supplement au code-barres 855571001082, is described by its US market label. If sold in France, it would be subject to 3 points of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- To check
5-hydroxytryptophan is listed in the Novel Food Catalogue as a novel food not yet authorised in the European Union: in the form covered by the entry, it should not be sold until authorised. The catalogue is informative; a declaration in France is not an authorisation.
Source: Novel Food Catalogue (status of products under Regulation (EU) 2015/2283), POL-NF-00063.
- Legal conditions
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Legal conditions
Hyssopus officinalis L.: L'huile essentielle de cette plante est interdite.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Arthur Andrew Medical
- Barcode
- 855571001082
- Form
- Capsule
- One serving
- 1 capsule
- Servings
- number of servings per day not stated
- Other ingredients (in English, as written)
- Cellulose, Calcium Caprylate, Maltodextrin
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Vitamin B6 | Vitamin | 50 mg |
| Magnesium | Mineral | 12 mg |
| FibroVera AHS Proprietary Blend | Blend | 490 mg |
| Fibrinolytic Enzyme blend | Blend | not stated |
| Serrapeptase | Enzyme | not stated |
| Protease | Enzyme | not stated |
| Bromelain | Enzyme | not stated |
| Papain | Enzyme | not stated |
| Nattokinase NSK | Enzyme | not stated |
| Estromin Hormonal Support Blend | Blend | not stated |
| Gamma-Linolenic Acid | Fatty acid | not stated |
| Diindolymethane | Other substance | not stated |
| 5-Hydroxytryptophan | Amino acid | not stated |
| Dehydroepiandrosterone | Hormone | not stated |
| Black Cohosh (Actaea racemosa) | Plant | not stated |
| Dong quai (Angelica sinensis) | Plant | not stated |
| Liver Cleanse | Blend | not stated |
| Milk Thistle (Silybum marianum) | Plant | not stated |
| Dandelion, Powder | Plant | not stated |
| Hyssop (Hyssopus officinalis) | Plant | not stated |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: FibroVera AHS
Entered into DSLD on 24 May 2013. Withdrawn from the US market on 22 September 2021 (according to the DSLD).- Active ingredient added : Cofactor Blend (quantity not stated)
- Active ingredient added : Proprietary Blend FibroVera AHS (730 mg)
- Active ingredient removed : 5-Hydroxytryptophan (quantity not stated)
- Active ingredient removed : Black Cohosh (quantity not stated)
- Active ingredient removed : Bromelain (quantity not stated)
- Active ingredient removed : Dandelion, Powder (quantity not stated)
- Active ingredient removed : Dehydroepiandrosterone (quantity not stated)
- Active ingredient removed : Diindolymethane (quantity not stated)
- Active ingredient removed : Dong quai (quantity not stated)
- Active ingredient removed : FibroVera AHS Proprietary Blend (490 mg)
- Active ingredient removed : Gamma-Linolenic Acid (quantity not stated)
- Active ingredient removed : Hyssop (quantity not stated)
- Active ingredient removed : Magnesium (12 mg)
- Active ingredient removed : Milk Thistle (quantity not stated)
- Active ingredient removed : Nattokinase NSK (quantity not stated)
- Active ingredient removed : Papain (quantity not stated)
- Active ingredient removed : Protease (quantity not stated)
- Active ingredient removed : Serrapeptase (quantity not stated)
- Active ingredient removed : Vitamin B6 (50 mg)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Serrapeptase
Read the warning, when it applies and the studies cited
SERRAPEPTASE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gastrointestinal lesions/ulcers, a kidney or liver disorder, or are having surgery (Bhagat et al. 2013; Chopra et al. 2009; Al- Khateeb and Nusair 2008; Mazzone et al. 1990).
Sources cited by Health Canada (4)
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
- Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
- Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or anti-inflammatory medications (Bhagat et al. 2013; Chopra et al. 2009; Al-Khateeb and Nusair 2008; Mazzone et al. 1990).
Sources cited by Health Canada (4)
- Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
- Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
Known adverse reactions
Stop use if rash, difficulty breathing, hypersensitivity and/or severe allergy occur (Bhagat et al. 2013; Balagi 2007).
Sources cited by Health Canada (1)
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- 5-Hydroxytryptophan
Read the warning, when it applies and the studies cited
5-HTP
Route of administration: Oral
Cautions and warnings
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking carbidopa or health products with serotonergic activity such as mood balance supplements, cough medication containing dextromethorphan, pain killers or medications for nausea or migraine (Mayo Clinic Staff 2022; Patel and Marzella 2017; Turner et al 2006).
Sources cited by Health Canada (3)
- Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
- Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Case report
- Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics 2006;109(3):325-338. PubMed Review article
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution while driving or using machinery, as you may experience drowsiness (Berardi et al. 2002).
Sources cited by Health Canada (1)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollings CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All uses (excluding weight management).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Condition of application: Weight management.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Condition of application: Healthy mood balance; Fibromyalgia symptoms.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a psychological disorder such as anxiety or depression.
Contraindications
Condition of application: All uses.
Do not use if you have scleroderma (Lampert et al. 1992; Sternberg et al. 1980).
Sources cited by Health Canada (2)
- Lampert A, Joly P, Thomine E, Ortoli JC, Lauret P. [Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam]. Annales de Dermatologie et de Vénéréologie 1992;119(3):209-211 (in French). PubMed Case report
- Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. New England Journal of Medicine 1980;303(14):782-787. PubMed Clinical trial
Do not use if you are taking antidepressants (Mayo Clinic Staff 2022; Patel and Marzella 2017).
Sources cited by Health Canada (2)
- Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
- Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Case report
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Weight management.
Do not use if you are pregnant (HC 2010).
Sources cited by Health Canada (2)
- HC 2010: Health Canada: Prenatal Nutrition Guidelines for health Professionals: Gestational weight gain [Accessed 2024 April 7]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-eng.pdf
- SC 2010 : Santé Canada : Lignes directrices sur la nutrition pendant la grossesse à l'intention des professionnels de la santé : Gain de poids pendant la grossesse. [Consulté le 7 avril 2024]. Disponible à : https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-fra.pdf
Known adverse reactions
When using this product you may experience gastrointestinal discomfort/disturbances (Turner et al. 2006; Byerley et al. 1987).
Sources cited by Health Canada (2)
- Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. Journal of Clinical Psychopharmacology 1987;7(3):127-137. PubMed Clinical trial
- Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics 2006;109(3):325-338. PubMed Review article
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience skin hardening, pain or stiffness of muscles or joints, tremors, agitation/confusion, or an increased heart rate (Boyer 2023; Varga 2023; Mayo Clinic Staff 2022; Patel and Marzella 2017; Das et al. 2004; Erner et al. 2003; Lampert et al. 1992; Sternberg et al. 1980).
Sources cited by Health Canada (8)
- Boyer EW. Serotonin syndrome (serotonin toxicity). UpToDate 2023 [Accessed 2023 October 18]. Available from: Available from : https://www.uptodate.com/.
- Das YT, Bagchi M, Bagchi D, Preuss HG. Safety of 5-hydroxy-L-tryptophan. Toxicology Letters 2004;150(1):111-122. PubMed Case report
- Erner RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin Syndrome and Other Serotonergic Disorders. Pain Medicine 2003;4(1): 63-74.
- Lampert A, Joly P, Thomine E, Ortoli JC, Lauret P. [Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam]. Annales de Dermatologie et de Vénéréologie 1992;119(3):209-211 (in French). PubMed Case report
- Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
- Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Case report
- Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. New England Journal of Medicine 1980;303(14):782-787. PubMed Clinical trial
- Varga J. Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate 2023 [Accessed 2023 October 18]. Available from : https://www.uptodate.com/.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Black Cohosh
Read the warning, when it applies and the studies cited
Black Cohosh - Actaea Racemosa
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or develop symptoms of liver trouble (EMA 2018, 2007; Lynch et al. 2006; Mills et al. 2006; Cohen et al. 2004; NIH 2004).
Sources cited by Health Canada (6)
- Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause: the Journal of the North American Menopause Society 2004;11(5):575-577. PubMed Case report
- EMA 2018: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC). European Union Herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome. March 2018. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf
- EMA 2007: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC) Annex 1. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root). London (UK): European Medicines Agency; May 20027. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-report/assessment-case-reports-connected-herbal-medicinal-products-containing-cimicifugae-racemosae-rhizoma-black-cohosh-root_en.pdf
- Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transplantation 2006;12(6):989-992. PubMed Case report
- Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. New York (NY): Taylor and Francis; 2006.
- NIH 2004: National Institutes of Health. Workshop on the Safety of Black Cohosh in Clinical Studies. Bethesda (MD): National Institutes of Health, Department of Health and Human Services; November 22, 2004. [Accessed 2024 December 3]. Available from: https://files.nccih.nih.gov/s3fs-public/news/blackcohosh_mtngsumm.pdf
Contraindications
Do not use if you are pregnant (Brinker 2010; Hoffmann 2003; Tilgner 1999).
Sources cited by Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
- Tilgner S. Herbal Medicine from the Heart of the Earth Creswell (OR): Wise Acre Press; 1999.
- Dong quai
Read the warning, when it applies and the studies cited
DONG QUAI - ANGELICA SINENSIS
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (NS 2021).
Sources cited by Health Canada (1)
- NS 2021: Natural Standard. Dong quai (Angelica sinensis [Oliv.] Diels). [Accessed 2023 December 31]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=936
Ask a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking any medications including blood thinners, birth control pills or hormone therapy (NS 2021; Brinker 2010; WHO 2002).
Sources cited by Health Canada (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- NS 2021: Natural Standard. Dong quai (Angelica sinensis [Oliv.] Diels). [Accessed 2023 December 31]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=936
- WHO 2002: World Health Organization Monographs on Selected Medicinal Plants - Volume 2. Geneva (CH): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la santé. Monographs on Selected Medicinal Plants - Volume 2. Genève (CH): Organisation mondiale de la santé; 2002.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have serious or major conditions, any type of acute infection, deficiency or excess (HC 2022).
Sources cited by Health Canada (2)
- HC 2022: Health Canada. Traditional Chinese Medicine Ingredients monograph. [Accessed 2024 July 10]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=tcm&lang=eng
- SC 2022: Santé Canada. Monographie sur les Ingrédients de la Médecine Traditionnelle Chinoise. [Consulté le 10 juillet 2024]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=tcm&lang=fre
When using this product avoid exposure to the sun (NS 2021; Thorne 2004).
Sources cited by Health Canada (2)
- NS 2021: Natural Standard. Dong quai (Angelica sinensis [Oliv.] Diels). [Accessed 2023 December 31]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=936
- Thorne 2004: Thorne Research Inc. Monograph Angelica sinensis (Dong quai). Alternative Medicine Review 2004;9(4):429-433.
Contraindications
Do not use if you are pregnant (NS 2021; WHO 2002).
Sources cited by Health Canada (4)
- NS 2021: Natural Standard. Dong quai (Angelica sinensis [Oliv.] Diels). [Accessed 2023 December 31]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=936
- WHO 2002: World Health Organization Monographs on Selected Medicinal Plants - Volume 2. Geneva (CH): World Health Organization; 2002.
- Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
- OMS 2002: Organisation mondiale de la santé. Monographs on Selected Medicinal Plants - Volume 2. Genève (CH): Organisation mondiale de la santé; 2002.
Do not use if you have diarrhea, hemorrhagic diseases or heavy periods (NS 2021, Bensky et al. 2004; Chen and Chen 2004; WHO 2002).
Sources cited by Health Canada (6)
- Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
- Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.
- NS 2021: Natural Standard. Dong quai (Angelica sinensis [Oliv.] Diels). [Accessed 2023 December 31]. Available from: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=936
- WHO 2002: World Health Organization Monographs on Selected Medicinal Plants - Volume 2. Geneva (CH): World Health Organization; 2002.
- Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
- OMS 2002: Organisation mondiale de la santé. Monographs on Selected Medicinal Plants - Volume 2. Genève (CH): Organisation mondiale de la santé; 2002.
Known adverse reactions
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen, or if new symptoms develop such as breast pain or any changes in menstrual cycles (Brinker 2010; Schumacher et al. 2007; Thorne 2004; Russell et al. 2002).
Sources cited by Health Canada (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Russell L, Hicks GS, Low AK, Shepherd JM, Brown CA. Phytoestrogens: a viable option? The American Journal of the Medical Sciences 2002;324(4):185-188. PubMed Review article
- Schumacher M, Guennoun R, Ghoumari A, Massaad C, Robert F, El-Etr M, Akwa Y, Rajkowski K, and Baulieu E. Novel perspectives for progesterone in Hormone Replacement Therapy, with special reference to the nervous system. Endocrine Reviews 2007;28:387-439. PubMed Review article
- Thorne 2004: Thorne Research Inc. Monograph Angelica sinensis (Dong quai). Alternative Medicine Review 2004;9(4):429-433.
- Milk Thistle
Read the warning, when it applies and the studies cited
MILK THISTLE - SILYBUM MARIANUM
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).
Sources cited by Health Canada (2)
- Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
- Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).
- Hyssop
Read the warning, when it applies and the studies cited
Hyssop - Hyssop Officinalis
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Contraindications
Do not use if you are pregnant (Gardner and McGuffin 2013; Bradley 2006).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Has the product changed? Photograph the packaging.
Brand : Arthur Andrew Medical
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “FibroVera AHS (Arthur Andrew Medical): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/855571001082-fibrovera-ahs-arthur-andrew-medical, updated 23 February 2025.